Obesity Drug Coverage In ACA Plans May Expand With Shift In Treatment Classification Standard
Executive Summary
Current drug classification standard was originally designed for the Medicare Part D program, which does not cover obesity drugs.
You may also be interested in...
‘Essential’ Drug Coverage Including Obesity Treatments Make Sense For ACA Plans, CMS Says
But the Centers for Medicare and Medicaid Services wants to see data first on how promoting coverage of the new obesity drugs would impact uptake, plan costs and beneficiary premiums.
Copay Maximizers May Be Restricted In Small Private Plans Under CMS Proposal: Will Broader Impact Follow?
The Centers for Medicare and Medicaid Services requests stakeholder feedback on how extensively copay maximizers are being used by insurers, which could help pave the way for restrictions on large employer and self-insured plans.
Wegovy’s Cardiovascular Benefits May Improve, But Not Transform, Insurance Coverage In Obesity
Novo Nordisk’s obesity drug lowered adverse cardiovascular events by an impressive 20% in a pivotal study. However, payers may still want data on how paying for obesity drugs could lower their overall medical expenses.